Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06926634 · ClinicalTrials.gov registry record · Phase 2
Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)
A Phase 2 study of High Grade Neuroendocrine Neoplasms, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 2
- Study locations
NCT06926634 is a Phase 2 study of High Grade Neuroendocrine Neoplasms that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 32 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06926634, a Phase 2 study of High Grade Neuroendocrine Neoplasms, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 2
- Study locations
Study Summary
The investigators hypothesize that zanzalintinib maintenance therapy after initial cytotoxic chemotherapy can prolong the progression-free survival (PFS) in patients with high-grade NENs.
Conditions Studied
Interventions
- DRUG Zanzalintinib
Study Locations (2)
Minnesota
- Mayo Clinic - Rochester - Rochester
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-12-09 |
| Est. Completion | 2034-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06926634
The ClinicalTrials.gov registry entry for NCT06926634 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High Grade Neuroendocrine Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Zanzalintinib is the first listed.
NCT06926634 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, Missouri.
Frequently Asked Questions
What is clinical trial NCT06926634 about?
NCT06926634 is a clinical study titled "Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)". The investigators hypothesize that zanzalintinib maintenance therapy after initial cytotoxic chemotherapy can prolong the progression-free survival (PFS) in patients with high-grade NENs.
What is the current status of trial NCT06926634?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2025-12-09. Estimated completion is 2034-12-31.
What conditions does trial NCT06926634 study?
This clinical trial studies the following conditions: High Grade Neuroendocrine Neoplasms.
What interventions are being tested in trial NCT06926634?
The interventions under investigation include: Zanzalintinib (DRUG).
Who is sponsoring clinical trial NCT06926634?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06926634 being conducted?
This trial has 2 study locations across Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Grade Neuroendocrine Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.